Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
serplulimab + fruquintinib + capecitabine + oxaliplatin
- Development stage
- Unknown
- Lead developer
- Henlius
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Serplulimab + fruquintinib + XELOX is an investigational combination regimen being evaluated as a first-line treatment for patients with RAS/BRAF-mutated unresectable advanced metastatic colorectal cancer (mCRC). The regimen consists of serplulimab (a humanized anti-PD-1 monoclonal antibody), fruquintinib (a selective small-molecule inhibitor of VEGFR-1, -2, and -3), and XELOX chemotherapy (capecitabine and oxaliplatin). This combination aims to enhance anti-tumor activity by combining immune checkpoint inhibition, anti-angiogenesis, and cytotoxic chemotherapy, potentially overcoming the resistance typically seen in RAS/BRAF-mutated mCRC.
- Other names
- serplulimab + fruquintinib + XELOXFruquintinib Combined With Serplulimab and Chemotherapy
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)PDCD1 (Programmed cell death protein 1 receptor)VEGFR-1 (Vascular endothelial growth factor receptor 1)DNAVEGFR4 (Vascular endothelial growth factor Receptor-3)TS (Thymidylate synthase)
Beyond the preview
Go deeper on serplulimab + fruquintinib + capecitabine + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on serplulimab + fruquintinib + capecitabine + oxaliplatin.